These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37699222)

  • 1. Reply to the letter to the editor "Clarifications on the safety of dexrabeprazole vs. omeprazole in the treatment of gastroesophageal reflux disease".
    Abdo-Francis JM
    Gac Med Mex; 2023; 159(4):366. PubMed ID: 37699222
    [No Abstract]   [Full Text] [Related]  

  • 2. Clarifications on the safety of dexrabeprazole vs. omeprazole in the treatment of gastroesophageal reflux disease.
    López-Suárez CM
    Gac Med Mex; 2023; 159(4):364-365. PubMed ID: 37699220
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease.
    Pai V; Pai N
    World J Gastroenterol; 2007 Aug; 13(30):4100-2. PubMed ID: 17696229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
    Thjodleifsson B; Rindi G; Fiocca R; Humphries TJ; Morocutti A; Miller N; Bardhan KD;
    Aliment Pharmacol Ther; 2003 Feb; 17(3):343-51. PubMed ID: 12562446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
    Holtmann G; Bytzer P; Metz M; Loeffler V; Blum AL
    Aliment Pharmacol Ther; 2002 Mar; 16(3):479-85. PubMed ID: 11876701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten mg dexrabeprazole daily is as effective as 20 mg rabeprazole daily.
    Kanakia R; Jain S
    World J Gastroenterol; 2008 Jul; 14(28):4586-7. PubMed ID: 18680246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.
    Kahrilas PJ; Miner P; Johanson J; Mao L; Jokubaitis L; Sloan S
    Dig Dis Sci; 2005 Nov; 50(11):2009-18. PubMed ID: 16240208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety comparative study of dexrabeprazole vs. esomeprazole for the treatment of gastroesophageal reflux disease.
    Abdo-Francis JM; Cabrera-Álvarez G; Martínez-Torres H; Remes-Troche JM
    Gac Med Mex; 2022; 158(6):423-429. PubMed ID: 36657136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of efficacy and safety of two modes of maintenance therapy with rabeprazole in patients with gastroesophageal reflux disease (GERD) of degrees 0 and 1].
    Minushkin ON; Maslovskiĭ LV; Anikina NIu; Shuleshova AG
    Eksp Klin Gastroenterol; 2005; (2):29-35. PubMed ID: 15932152
    [No Abstract]   [Full Text] [Related]  

  • 11. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.
    Bytzer P; Morocutti A; Kennerly P; Ravic M; Miller N;
    Scand J Gastroenterol; 2006 Oct; 41(10):1132-40. PubMed ID: 16990197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
    Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
    Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.
    Johnson M; Guilford S; Libretto SE;
    Curr Med Res Opin; 2002; 18(5):303-10. PubMed ID: 12240793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J; Dodd S; Durkin M; Sloan S
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
    Pace F; Coudsy B; DeLemos B; Sun Y; Xiang J; LoCoco J; Casalini S; Li H; Pelosini I; Scarpignato C
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):845-51. PubMed ID: 21900784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
    Lim PW; Goh KL
    J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S61-8. PubMed ID: 15324384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of rabeprazole in gastroesophageal reflux disease: report of a multicenter study.
    Kar P; Chandrashekar N; Devi S; Bhatia SJ; Alvares JF; Taneja A; Towar A
    Indian J Gastroenterol; 2003; 22(4):153. PubMed ID: 12962446
    [No Abstract]   [Full Text] [Related]  

  • 20. A postmarketing surveillance study of dexrabeprazole in the treatment of acid peptic disorders.
    Jain SC;
    J Indian Med Assoc; 2009 Feb; 107(2):111-3. PubMed ID: 19585824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.